255 related articles for article (PubMed ID: 8939141)
21. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
[TBL] [Abstract][Full Text] [Related]
22. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
23. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
24. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
25. Interferon beta-1a in relapsing-remitting multiple sclerosis.
Blumhardt L
Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
[TBL] [Abstract][Full Text] [Related]
26. The role of interferons in the treatment of multiple sclerosis.
Kelley CL
J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
[TBL] [Abstract][Full Text] [Related]
27. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
28. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
29. Interferon beta-1b for the treatment of multiple sclerosis.
Petri T; Weber-Diehl F
J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
[No Abstract] [Full Text] [Related]
30. Trial of interferon-beta in multiple sclerosis stopped early.
Bonn D
Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
[No Abstract] [Full Text] [Related]
31. Interferon beta-1b.
Goodkin DE
Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
[No Abstract] [Full Text] [Related]
32. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
33. Interferon beta-1B--hope or hype?
Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
[No Abstract] [Full Text] [Related]
34. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
Romero López J; Maciñeiras Montero JL
Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
[No Abstract] [Full Text] [Related]
35. [Interferon beta-1b. New therapy for patients with secondary progressive multiple sclerosis].
Nervenarzt; 1999 May; 70(5 Suppl):1-12. PubMed ID: 10368803
[No Abstract] [Full Text] [Related]
36. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
37. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
38. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
[No Abstract] [Full Text] [Related]
40. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
